Veeva Systems Business Summary

Veeva Systems Inc. (VEEV) operates a high-margin, industry-specific cloud model, generating approximately 84% of its revenue from recurring software subscriptions and the remainder from professional services. The company’s business is divided into two core segments: Veeva Development Cloud, which provides unified suites for clinical, regulatory, quality, and safety functions, and Veeva Commercial Cloud, featuring the proprietary Vault CRM, Veeva Compass data, and the recently launched Veeva AI Agents. A pivotal strategic shift is currently underway as the company migrates its massive CRM install base from the Salesforce platform to its own native Vault platform, a move that enhances vertical integration and margin potential. Veeva competes primarily with IQVIA in data and commercial services, Salesforce’s "Agentforce Life Sciences" in the CRM space, and Oracle and Medidata (Dassault Systèmes) in clinical trial management. As of early 2026, Veeva maintains a dominant market position as the de facto operating system for the life sciences industry, distinguished by its "industry cloud" specialization and deep regulatory compliance features. The company was founded in 2007 by Peter Gassner and Matt Wallach, with Gassner continuing to serve as CEO. Gassner’s pedigree includes pivotal roles as Senior Vice President of Technology at Salesforce and a lead architect at PeopleSoft, providing him with deep expertise in multi-tenant cloud architecture. The current executive leadership team includes Chief Financial Officer Brian Van Wagener, who assumed the role in late 2024, and Tom Schwenger, who serves as President and Chief Customer Officer. Other key figures include Nitsa Zuppas, President and Chief of Staff, and Paul Shawah, Senior Vice President of Commercial Strategy. Veeva’s board of directors is chaired by Gordon Ritter, a founder of early investor Emergence Capital, and includes industry veterans such as former CFO Tim Cabral and co-founder Matt Wallach. This leadership group is currently focused on a long-term goal of reaching a $6 billion revenue run-rate by 2030, leveraging a debt-free balance sheet and a specialized workforce to maintain its lead in the highly regulated global biopharma sector.